Baker McKenzie is representing Servier, an independent international pharmaceutical group governed by a foundation, on its definitive agreement to acquire Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a commercial stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with life threatening diseases, for approximately USD 2.5 billion.
Under the terms of the merger agreement, Servier will commence a cash tender offer to acquire all of the issued and outstanding shares of Day One’s common stock for $21.50 per share in cash. Upon the successful completion of the tender offer, Servier will acquire any shares not acquired in the tender through a second-step merger for the same consideration per share paid in the tender offer. Subject to customary closing conditions, the deal is expected to close in the second quarter of 2026.
The acquisition strengthens Servier’s oncology portfolio and expands its pipeline with programs targeting adult and pediatric cancers with high unmet medical needs, reinforcing Servier’s ambition to become a leading innovator in oncology.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
